Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's ...

As generic versions of AstraZeneca’s blockbuster drug ticagrelor prepare to enter the market, The BMJ raises fresh concerns over the integrity of the clinical trials that underpinned its approval.

In a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in ...

MEDICS have raised concerns over a drug taken by millions to prevent heart attacks and strokes, claiming key safety data was “misreported” by its manufacturer AstraZeneca.

In a follow-up investigation into the multibillion-dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in key platelet studies used in its FDA approval.

Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.In this m ...

Ticagrelor reversibly inhibits the P2Y12 receptors on platelets, preventing platelet activation and, consequently, aggregation. Unlike the thienopyridines, it does not require metabolic activation.

Ticagrelor inhibited MRSA, MRSE, and VRE biofilm formation in a dose-dependent manner. Biofilm mass was reduced by more than 85% after exposure to ticagrelor 20 μg/mL, the researchers report.

Ticagrelor monotherapy after 3-month dual antiplatelet therapy was not associated with greater risk for repeat revascularization or MACCE at 1 year after PCI vs. continued DAPT, a speaker reported.

Ticagrelor, a direct-acting antiplatelet agent that is not dependent on metabolic activation, reversibly binds and inhibits the P2Y 12 receptor on platelets. 8,9 A trial of ticagrelor alone in ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major ...

Background: Dual antiplatelet therapy is the standard of care for acute coronary syndrome, but uncertainty exists regarding the optimal regimen for patients in North America. We sought to compare the ...